A detailed history of New Edge Advisors, LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 1,068 shares of GH stock, worth $31,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,068
Previous 367 191.01%
Holding current value
$31,484
Previous $9,000 144.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$17.13 - $26.91 $12,008 - $18,863
701 Added 191.01%
1,068 $22,000
Q4 2023

Feb 13, 2024

BUY
$21.58 - $29.5 $4,143 - $5,664
192 Added 109.71%
367 $9,000
Q3 2023

Nov 14, 2023

BUY
$25.8 - $39.97 $3,844 - $5,955
149 Added 573.08%
175 $5,000
Q2 2023

Aug 14, 2023

SELL
$20.94 - $38.01 $11,914 - $21,627
-569 Reduced 95.63%
26 $0
Q1 2023

May 12, 2023

SELL
$22.92 - $33.76 $16,204 - $23,868
-707 Reduced 54.3%
595 $13,000
Q4 2022

Feb 14, 2023

BUY
$25.44 - $59.78 $33,122 - $77,833
1,302 New
1,302 $35,000
Q3 2021

Oct 29, 2021

SELL
$98.77 - $132.17 $336,410 - $450,171
-3,406 Closed
0 $0
Q2 2021

Jul 22, 2021

BUY
$109.77 - $165.68 $373,876 - $564,306
3,406 New
3,406 $423,000
Q1 2021

Apr 26, 2021

SELL
$127.04 - $179.1 $1.21 Million - $1.71 Million
-9,529 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$99.96 - $135.93 $952,518 - $1.3 Million
9,529 New
9,529 $1.23 Million
Q2 2020

Jul 29, 2020

SELL
$60.49 - $97.5 $771,610 - $1.24 Million
-12,756 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$59.04 - $88.81 $4,487 - $6,749
76 Added 0.6%
12,756 $888,000
Q4 2019

Jan 31, 2020

BUY
$59.49 - $82.78 $754,333 - $1.05 Million
12,680 New
12,680 $990,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.01B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.